CheckMate 816, 2022 NCT02998528
nivolumab plus SoC (n=179) vs. placebo plus SoC (n=179)
randomized controlled trial
nivolumab plus platinum doublet
nivolumab 360 mg plus histology-based platinum doublet chemotherapy every three weeks for up to three doses
placebo plus platinum doublet
placebo plus platinum doublet chemotherapy every three weeks for up to three doses, followed by surgery
NSCLC neoadjuvant setting
open label
P3